Preparation, physicochemical, and retinal anti-angiogenic evaluation of poloxamer hydrogel containing dexamethasone/avastin-loaded chitosan-N-acetyl-L-cysteine nanoparticles.
Avastin
Chitosan-N-acetyl-L-cysteine
Dexamethasone
Hydrogel
Poloxamer
Retinopathy
Journal
International journal of biological macromolecules
ISSN: 1879-0003
Titre abrégé: Int J Biol Macromol
Pays: Netherlands
ID NLM: 7909578
Informations de publication
Date de publication:
01 Nov 2022
01 Nov 2022
Historique:
received:
16
05
2022
revised:
07
09
2022
accepted:
11
09
2022
pubmed:
19
9
2022
medline:
15
10
2022
entrez:
18
9
2022
Statut:
ppublish
Résumé
This study was meant to describe a Poloxamer hydrogel combining Chitosan-N-acetyl-L-cysteine (CNAC) nanoparticles to increase loading and sustained intravitreal administration of Avastin macromolecule. To increase the drug's efficacy and reduce the interfacial fluid pressure in a formulation, dexamethasone was used. To do so, CNAC was synthesized. Then, Avastin- loaded CNAC nanoparticles were prepared and optimized. The resulting hydrogel's sol-gel transition time and viscosity were determined using poloxamer and hydroxypropylmethylcellulose (HPMC). In vitro and in vivo investigations of Avastin-loaded CNAC nanoparticles and hydrogel comprising dexamethasone/Avastin-loaded CNAC nanoparticles were determined. In vitro, the drug release profile of optimized hydrogel containing Avastin-loaded CNAC nanoparticles was sustained and controlled over 256 h. The obtained results point to poloxamer/HPMC (18 %/0.5 %) as the best formulations for this hydrogel to develop a sol-gel transition. About 97 % of dexamethasone was released from the hydrogel within 18 h. In vivo results indicated that the optimized formulation compared with free Avastin could improve Diabetic retinopathy (DR). Consequently, we infer that this new drug delivery method may enhance Avastin intravitreal administration, lowering the frequency, danger, and expense of heavy intravitreal injections and resulting in improved treatment of posterior eye segment neovascularization and concomitant vitreoretinal disorders.
Identifiants
pubmed: 36116595
pii: S0141-8130(22)02032-3
doi: 10.1016/j.ijbiomac.2022.09.101
pii:
doi:
Substances chimiques
Acetylcysteine
WYQ7N0BPYC
Bevacizumab
2S9ZZM9Q9V
Chitosan
9012-76-4
Dexamethasone
7S5I7G3JQL
Hydrogels
0
Hypromellose Derivatives
3NXW29V3WO
Poloxamer
106392-12-5
chitosan-N-acetyl-L-cysteine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1605-1618Informations de copyright
Copyright © 2022. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of competing interest Sayed Abolfazl Mostafavi reports financial support was provided by Isfahan University of Medical Sciences. Sayed Abolfazl Mostafavi reports a relationship with Isfahan University of Medical Sciences that includes: funding grants.